Safety and Efficacy of Bleomycin Sclerotherapy for Microcystic Lymphatic Malformation

CardioVascular and Interventional Radiology

Volumn 37, Issue 6, 2014, Pages 1476-1481

  Chaudry, Gulraiz ^a   Guevara, Carlos J ^a   Rialon, Kristy L ^a   Kerr, Cindy ^a   Mulliken, John B ^a   Greene, Arin K ^a   Fishman, Steven J ^a   Boyer, Debra ^a   Alomari, Ahmad I ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Nonvascular interventions; Pediatric; Sclerotherapy

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; BLEOMYCIN;

ADOLESCENT; ADULT; CHILD; FEMALE; HUMAN; INFANT; LUNG FUNCTION TEST; LYMPHATIC ABNORMALITIES; MALE; PRESCHOOL CHILD; PROCEDURES; RETROSPECTIVE STUDY; SCLEROTHERAPY; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LYMPHATIC ABNORMALITIES; MALE; RADIOGRAPHY, THORACIC; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; SCLEROTHERAPY; TREATMENT OUTCOME;

EID: 84919759491     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-014-0932-z     Document Type: Article

References (21)

1. Burrows PE, Mitri RK, Alomari A et al (2008) Percutaneous sclerotherapy of lymphatic malformations with doxycycline. Lymphat Res Biol 6:209–216
2. Chaudry G, Burrows PE, Padua HM, Dillon BJ, Fishman SJ, Alomari AI (2011) Sclerotherapy of abdominal lymphatic malformations with doxycycline. J Vasc Interv Radiol 22:1431–1435
3. Alomari AI, Karian VE, Lord DJ, Padua HM, Burrows PE (2006) Percutaneous sclerotherapy for lymphatic malformations: a retrospective analysis of patient-evaluated improvement. J Vasc Interv Radiol 17:1639–1648
4. Sainsbury DC, Kessell G, Fall AJ, Hampton FJ, Guhan A, Muir T (2011) Intralesional bleomycin injection treatment for vascular birthmarks: a 5-year experience at a single United Kingdom unit. Plast Reconstr Surg 127:2031–2044
5. Fishman SJ (2013) Slow-flow vascular malformations. In: Mulliken JB, Burrows PE, Fishman SJ (eds) Mulliken & Young’s vascular anomalies: hemangiomas and malformations, vol 2. Oxford University Press, Oxford
6. Burrows PE (2013) Percutaneous treatment of slow-flow vascular malformations. In: Mulliken JB, Burrows PE, Fishman SJ (eds) Mulliken & Young’s vascular anomalies: hemangiomas and malformations, 2nd edn. Oxford University Press, New York, pp 661–710
7. Yamamoto T, Katayama I (2011) Vascular changes in bleomycin-induced scleroderma. Int J Rheumatol 2011:270938
8. Ohta H, Chiba S, Ebina M, Furuse M, Nukiwa T (2012) Altered expression of tight junction molecules in alveolar septa in lung injury and fibrosis. Am J Physiol Lung Cell Mol Physiol 302:L193–L205
9. Hashimoto N, Phan SH, Imaizumi K et al (2010) Endothelial–mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 43:161–172
10. Zhang W, Chen G, Ren JG, Zhao YF (2013) Bleomycin induces endothelial mesenchymal transition through activation of mTOR pathway: a possible mechanism contributing to the sclerotherapy of venous malformations. Br J Pharmacol 170(6):1210–1220
11. Yura J, Hashimoto T, Tsuruga N, Shibata K (1977) Bleomycin treatment for cystic hygroma in children. Nihon Geka Hokan 46:607–614
12. Yang Y, Sun M, Ma Q et al (2011) Bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations. J Vasc Surg 53:150–155
13. Perkins JA, Manning SC, Tempero RM et al (2010) Lymphatic malformations: review of current treatment. Otolaryngol Head Neck Surg 142:795–803, 803.e1
14. O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A (2003) Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 14:91–96
15. Comis RL (1992) Bleomycin pulmonary toxicity: current status and future directions. Semin Oncol 19:64–70
16. Blum RH, Carter SK, Agre K (1973) A clinical review of bleomycin—a new antineoplastic agent. Cancer 31:903–914
17. Muir T, Kirsten M, Fourie P, Dippenaar N, Ionescu GO (2004) Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations. Pediatr Surg Int 19:766–773
18. Ionescu G, Mabeta P, Dippenaar N, Muir T, Fourie P, Shelver G (2008) Bleomycin plasma spill-over levels in paediatric patients undergoing intralesional injection for the treatment of haemangiomas. S Afr Med J 98:539–540
19. Sleijfer S (2001) Bleomycin-induced pneumonitis. Chest 120:617–624
20. Atwa K, Abuhasna S, Shihab Z, Hashaykeh N, Hasan R (2010) Acute pulmonary toxicity following intralesional administration of bleomycin for a lymphovenous malformation. Pediatr Pulmonol 45:192–196
21. Mertens AC, Yasui Y, Liu Y et al (2002) Pulmonary complications in survivors of childhood and adolescent cancer. A report from the Childhood Cancer Survivor Study. Cancer 95:2431–2441